Interface Biologics Completes Pre-IND Meeting with U.S. FDA

Interface Biologics announced a positive pre-IND (Investigational New Drug) meeting with the U.S. FDA for its novel dexamethasone intravitreal implant for the treatment of posterior inflammatory eye diseases. 

Click here to read more

Previous
Previous

MediSeen Launches Home Healthcare Platform

Next
Next

U of T partners with National Research Council to Create National Innovation Hub